A bearish article published Monday afternoon on Seeking Alpha claimed that LGND stock has the potential to lose 100% of its value based on a severe competitive threat to Promacta and ‘going concern’ risk. However, Roth Capital analyst …
On Wednesday, Ligand Pharmaceuticals (LGND) earned a positive adjustment to its Relative Strength (RS) Rating, from 73 to 82. XAutoplay: On | Off This unique rating tracks market leadership by using a 1 (worst) to 99 (best) score that …
Below is a chart showing RAD's trailing twelve month trading history, with the $5 strike highlighted in orange: And Ligand Pharmaceuticals Inc (LGND) options are showing a volume of 1,466 contracts thus far today. That number of contracts …
Ligand Pharmaceuticals (NASDAQ:LGND) last released its earnings results on Tuesday, May 9th. The SI to Ligand Pharmaceuticals's float is 25.18%. The stock increased 0.55% or $0.67 during the last trading session, reaching …
Nov 21, 2016 07:30 AM Ligand Partner Retrophin Reports Additional Positive Data from Phase 2 DUET Study of Sparsentan in Focal Segmental Glomerulosclerosis at ASN Kidney Week 2016 Nov 21, 2016 06:42 AM Roth Capital …
Trade what you see, not what you believe. The strength in the averages and leaders may ... Among the names, Ligand Pharmaceuticals LGND, +0.19% is a rare leader that sets up in a base, this one of five weeks. The developer of drugs …
The stock declined 1.55% or $0.02 reaching $1.27 on the news. About 52,957 shares traded. It has underperformed by 12.65% the S&P500. Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announces it will receive $10 million from …
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) is a unique biotech play that offers long-term staged growth profile, according to a note from Stephens, which initiated coverage of the stock with an Overweight (Volatile) rating. The …
Our equity analysts have no choice but to rate the stock NEUTRAL, despite David Knott’s ... reveal that 175 hedge …